Monday, October 26, 2026

Capital Markets & M&A

2 articles

TPG Raises $51 Billion in 2025 as Private Equity Firms Pivot to Credit and Alternative Strategies

TPG Raises $51 Billion in 2025 as Private Equity Firms Pivot to Credit and Alternative Strategies

TPG raised $51 billion in 2025, up from $30 billion the previous year, while cutting private equity concentration from 80% to 40% of AUM since its IPO. The shift reflects broader industry diversification into credit markets, with Third Point launching new private credit funds and Ancient Financial Holdings acquiring F&G Life Re as alternative asset managers chase growth beyond traditional buyouts.

ViaNews Editorial Team (Markets)•
Nvidia Backs $1.17B AI Infrastructure Deal as SoftBank-Marvell Realignment Signals Chip Sector Consolidation

Nvidia Backs $1.17B AI Infrastructure Deal as SoftBank-Marvell Realignment Signals Chip Sector Consolidation

Nvidia committed $1.17B to AI infrastructure investments while SoftBank pursues strategic realignment with Marvell, marking institutional capital flows into semiconductor supply chains. Rezolve Ai reported 650+ enterprise clients processing billions of API calls, demonstrating commercial-scale generative AI deployment. The moves reflect investor confidence in sustained AI demand despite organic search traffic declining up to 50% as AI-powered search replaces conventional SEO.

ViaNews Editorial Team (Markets)•
What we know · the intelligence behind this page
Live from the substrate
What we're seeing
Q4 2026 Biotech Catalyst Window: ESMO Data, the Ivonescimab PDUFA and Small-Cap Delistings
Mid-October to November 2026 is a dense catalyst period for clinical-stage biotech. Positive late-stage readouts (ALOFT-IPF, TELIGAN, MIUDELLA, the duvakitug extension) and the ESMO 2026 presentations lead up to the FDA's 14 November PDUFA date for the ivonescimab BLA. At the opposite end of the market, Spago Nanomedical is moving to delist from Nasdaq First North, which shows how hard it is for micro-cap developers to fund themselves. Value is concentrating in companies with late-stage data and near-term regulatory outcomes.
Our read on the data ›
Signals we're tracking
EPKINLY Regulatory-Clinical Success Cascade
High probability of expanded label indications, additional combination approvals, and competitive positioning strength in follicular lymphoma market. Predicts positive commercial uptake and potential accelerated review for related indications.
Patterns we're watching ›
Where sources disagree
Ford Motor Company
Both facts give cash for Ford Motor Company at the same point in time (2025-12-31; FY 2025 year-end and Q4 2025 year-end are the same date). Both are labelled USD, but the values are 23,356,000,000 and 23.356, which cannot both be true in USD. The two numbers agree once the second is read as billions (23.356 bn = 23,356,000,000), so the economic content is consistent and the conflict is a unit/scale error in the Q4 2025 record. The period is not the reason for the conflict: a Q4 and an FY figure at the same year-end date should match.
We flag conflicts openly ›
Recently verified
✓ Checked against the original source
4,994
facts traced to their source — and we flag the ones that don't hold up.
101 entities tracked4,994 facts checked against source5,500 source documents archived
Query this data → isubstrate.com